Glenmark Pharma gets USFDA approval for nervous system stimulant drug

Shares of Glenmark Pharma were trading 1.44 per cent lower at Rs 478.50 apiece on BSE.

Drug major Glenmark Pharma on Thursday said it has received final approval from the US health regulator for central nervous system stimulant drug Amphetamine Sulfate tablets.

The approved product is a generic version of Evekeo tablets of Arbor Pharmaceuticals LLC.

Glenmark Pharmaceuticals Ltd has been granted final approval by the United States Food and Drug Administration (USFDA) for Amphetamine Sulfate tablets USP in the strengths of 5 mg and 10 mg, it said in a regulatory filing.

Quoting IQVIA sales data for the 12 month period ending November 2020, Glenmark said Evekeo Tablets, 5 mg and 10 mg market achieved annual sales of approximately USD 21.5 million.

Glenmark's current portfolio consists of 168 products authorised for distribution in the US marketplace and 43 ANDA's pending approval with the USFDA.

Shares of Glenmark Pharma were trading 1.44 per cent lower at Rs 478.50 apiece on BSE.


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel